These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 32685037)

  • 1. EFFICACY AND SAFETY OF BASAL INSULIN THERAPY IN ROMANIAN PATIENTS WITH TYPE 2 DIABETES IN REAL-LIFE SETTINGS: A SUB-GROUP ANALYSIS OF DUNE STUDY.
    Cerghizan A; Amorin P; Catrinoiu D; Creteanu G; Adamescu E; Moise M
    Acta Endocrinol (Buchar); 2020; 16(1):43-48. PubMed ID: 32685037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Diabetes Unmet Need with Basal Insulin Evaluation (DUNE) study in type 2 diabetes: Achieving HbA1c targets with basal insulin in a real-world setting.
    Meneghini LF; Mauricio D; Orsi E; Lalic NM; Cali AMG; Westerbacka J; Stella P; Candelas Dea C; Pilorget V; Perfetti R; Khunti K;
    Diabetes Obes Metab; 2019 Jun; 21(6):1429-1436. PubMed ID: 30768845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Slow Titration and Delayed Intensification of Basal Insulin Among Patients with Type 2 Diabetes.
    Mocarski M; Yeaw J; Divino V; DeKoven M; Guerrero G; Langer J; Thorsted BL
    J Manag Care Spec Pharm; 2018 Apr; 24(4):390-400. PubMed ID: 29406841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unmet Needs in the Management of Type 2 Diabetes Mellitus Patients Starting Insulin Therapy with Basal or Premix Insulin in Routine Clinical Practice in Serbia.
    Beljić Živković TM; Đinđić BJ; Šuluburić Toljić DŽ; Vulović KTM; Udovičić DL; Zdravković DZ
    Diabetes Ther; 2019 Feb; 10(1):71-80. PubMed ID: 30450529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short-term intensive insulin therapy could be the preferred option for new onset Type 2 diabetes mellitus patients with HbA1c > 9.
    Weng J
    J Diabetes; 2017 Oct; 9(10):890-893. PubMed ID: 28661564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferiority trial.
    Heller S; Koenen C; Bode B
    Clin Ther; 2009 Oct; 31(10):2086-97. PubMed ID: 19922879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Continuous Subcutaneous Insulin Infusion (CSII) Pumps for Type 1 and Type 2 Adult Diabetic Populations: An Evidence-Based Analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2009; 9(20):1-58. PubMed ID: 23074525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Achieve control: a pragmatic clinical trial of insulin glargine 300 U/mL versus other basal insulins in insulin-naïve patients with type 2 diabetes.
    Oster G; Sullivan SD; Dalal MR; Kazemi MR; Rojeski M; Wysham CH; Sung J; Johnstone B; Cali AM; Wei LJ; Traylor L; Anhalt H; Hull M; Van Vleet J; Meneghini LF
    Postgrad Med; 2016 Nov; 128(8):731-739. PubMed ID: 27690710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Basal Insulin Dose Titration for Glycemic Control in Patients With Type 2 Diabetes Mellitus in Thailand: Results of the REWARDS Real-World Study.
    Deerochanawong C; Leelawattana R; Kosachunhanun N; Tantiwong P
    Clin Med Insights Endocrinol Diabetes; 2020; 13():1179551420935930. PubMed ID: 32774082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of iGlarLixi for Management of Type 2 Diabetes in Japanese Clinical Practice: SPARTA Japan, a Retrospective Observational Study.
    Matsuhisa M; Miyoshi H; Yabe D; Takahashi Y; Morimoto Y; Terauchi Y
    Diabetes Ther; 2023 Jan; 14(1):219-236. PubMed ID: 36422802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized, open-label, parallel-group evaluations of basal-bolus therapy versus insulin lispro premixed therapy in patients with type 2 diabetes mellitus failing to achieve control with starter insulin treatment and continuing oral antihyperglycemic drugs: a noninferiority intensification substudy of the DURABLE trial.
    Miser WF; Arakaki R; Jiang H; Scism-Bacon J; Anderson PW; Fahrbach JL
    Clin Ther; 2010 May; 32(5):896-908. PubMed ID: 20685497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world evidence on the use of a fixed-ratio combination of insulin glargine and lixisenatide (iGlarLixi) in people with suboptimally controlled type 2 diabetes in Romania: a prospective cohort study (STAR.Ro).
    Bala C; Cerghizan A; Mihai BM; Moise M; Guja C
    BMJ Open; 2022 May; 12(5):e060852. PubMed ID: 35623748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HbA1c target achievement in the elderly: results of the Titration and Optimization trial for initiation of insulin glargine 100 U/mL in patients with type 2 diabetes poorly controlled on oral antidiabetic drugs.
    Fritsche A; Anderten H; Pfohl M; Pscherer S; Borck A; Pegelow K; Bramlage P; Seufert J
    BMJ Open Diabetes Res Care; 2019; 7(1):e000668. PubMed ID: 31423316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of basal and premixed insulin on glycemic control in type 2 diabetes patients based on multicenter prospective real-world data.
    Peng Y; Xu P; Shi J; Zhang Y; Wang S; Zheng Q; Wang Y; Ke T; Li L; Zhao D; Dai Y; Dong Q; Ji B; Xu F; Gu W; Wang W
    J Diabetes; 2022 Feb; 14(2):134-143. PubMed ID: 35023626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study).
    Garber AJ; Wahlen J; Wahl T; Bressler P; Braceras R; Allen E; Jain R
    Diabetes Obes Metab; 2006 Jan; 8(1):58-66. PubMed ID: 16367883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of once-weekly basal insulin Fc in people with type 2 diabetes previously treated with basal insulin: a multicentre, open-label, randomised, phase 2 study.
    Frias J; Chien J; Zhang Q; Chigutsa E; Landschulz W; Syring K; Wullenweber P; Haupt A; Kazda C
    Lancet Diabetes Endocrinol; 2023 Mar; 11(3):158-168. PubMed ID: 36758572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world study on the effectiveness and safety of basal insulin IDegLira in type 2 diabetic patients previously treated with multi-injective insulin therapy.
    Persano M; Nollino L; Sambataro M; Rigato M; Negro I; Marchetto S; Paccagnella A
    Eur Rev Med Pharmacol Sci; 2021 Jan; 25(2):923-931. PubMed ID: 33577047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Effectiveness of an App (Insulia) in Recommending Basal Insulin Doses for French Patients With Type 2 Diabetes Mellitus: Longitudinal Observational Study.
    Nevoret C; Gervaise N; Delemer B; Bekka S; Detournay B; Benkhelil A; Bahloul A; d'Orsay G; Penfornis A
    JMIR Diabetes; 2023 Mar; 8():e44277. PubMed ID: 36749650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of insulin glargine added to a fixed-dose combination of metformin and a dipeptidyl peptidase-4 inhibitor: results of the GOLD observational study.
    Seufert J; Pegelow K; Bramlage P
    Vasc Health Risk Manag; 2013; 9():711-7. PubMed ID: 24259985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adding Prandial Insulin to Basal Insulin Plus Oral Antidiabetic Drugs in Chinese Patients with Poorly Controlled Type 2 Diabetes Mellitus: An Open-Label, Single-Arm Study.
    Jin Y; Sun X; Zhao X; Zhu T
    Diabetes Ther; 2017 Jun; 8(3):611-621. PubMed ID: 28349442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.